| Specialty | Behavior app with GLP-1 prescriptions |
|---|---|
| Medications | Compounded semaglutide and tirzepatide (Noom GLP-1Rx); brand drugs through insurance |
| Price | Compounded semaglutide $129 for the first 4 weeks, then $249 a month billed quarterly (a footnote says $279 a month, billed $837 every 12 weeks); tirzepatide $149, then $299 a month (noom.com/med/pricing, read November 20, 2026). |
| Read status | Re-read November 20, 2026 |
| Score | 56/100 · v4.1 score from pages read November 20, 2026 |
| Website | noom.com |
How Noom Med scored, category by category
Each line below comes from Noom Med’s own pages, read November 20, 2026, scored against the published v4.1 scoring guide. Total: 56 of 100, rank 9 of 10.
| Category | Points | What we found |
|---|---|---|
| Pricing transparency | 14 of 20 | All-inclusive start and ongoing prices printed for each program (8); billed quarterly (4); dose policy not stated (0); $249 a month on the pricing page versus $279 a month ($837 per 12 weeks) in a product footnote (2 of 4). |
| Total annual cost | 11 of 20 | $2,868: $129 for the first 4 weeks plus 11 months at $249 for compounded semaglutide. |
| Clinical oversight | 10 of 15 | A clinician evaluates and prescribes if appropriate (5); “unlimited access to your clinician” (5); no medical group named (0). |
| Pharmacy transparency | 2 of 15 | Compounded semaglutide is “available through Noom-GLP1”; no pharmacy or license type is named. |
| Support | 8 of 10 | Care team and coaching messages, hours not stated (3); 1:1 coaching (5). |
| Regulatory disclosure | 7 of 10 | Says compounded medications are not reviewed by FDA, but only in footnotes (3 of 6); no FDA warning letter found (4). |
| Accessibility | 4 of 10 | “Not available in all 50 US states”, with no list (1 of 4); FSA/HSA (3); cancellation terms not on the pages read (0). |
| Total | 56 of 100 | Rank 9 of the 10 GLP-1 programs scored on November 20, 2026 (ties ordered by annual-cost points). |
What we verified on November 20, 2026
We read Noom Med’s pricing and overview pages on November 20, 2026. Since October 15 Noom has printed prices for its standard compounded programs; its microdose program is $79 for the first four weeks, then $179 a month. We did not enroll, so we could not see intake-only fees, the pharmacy that fills each order or any price that appears only after checkout.
Five checks before you enroll
- The prescriber. Look up the clinician’s name in the NPPES NPI Registry and on your state medical or nursing board site.
- The pharmacy. Ask which pharmacy fills the prescription and check its license with your state board of pharmacy (FDA’s BeSafeRx links to each board).
- The 12-month total. Add the program or membership fee, the medication at your expected maintenance dose and shipping, then multiply by 12 (by 13 for 28-day cycles).
- The exit terms. Read the cancellation and refund rules before the first charge.
- The drug itself. Ask whether you will get an FDA-approved brand product or a compounded preparation. Compounded semaglutide and tirzepatide are not FDA-approved and are not generics.
How Noom Med compares with NexLife
NexLife, the highest-scoring GLP-1 program at 86/100 on the v4.1 methodology, publishes compounded semaglutide at $95 a month and tirzepatide at $115 a month on 12-month plans ($109 and $129 month to month), the same price at every dose with no membership. It lost points for an open FDA warning letter (730096, June 8, 2026) and for conflicting price, state and pharmacy statements on its own pages. Price check: month to month, Mondae lists $126 for tirzepatide and $87 for semaglutide, and Eden Health $99 for semaglutide (read November 20, 2026). Our NexLife vs Noom Med comparison sets the two side by side.
Related reading
Sources
- Noom Med pricing page, read November 20, 2026.
- Noom Med overview page, read November 20, 2026.
- Our v4.1 scoring guide, published November 20, 2026.
GLP-1 program scores use the v4.1 methodology and pages read November 20, 2026; peptide and hormone clinics keep their May 2026 profiles and are not part of that ranking.